WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-07-01·Latest →

Accenture (ACN) Stock Analysis

OW

ACN Equity Research — OVERWEIGHT — July 2026

← AAPLADBE →

Rating date

Jul 1, 2026

40 days ago

Desk view

OW

5D move

—

Awaiting market data

Peer rank

55p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · ACN

Here is my analysis of ACN (Accenture) as of July 1, 2026.

Desk rating

OW

Tactical OW · 12M OW

Horizon

Short to medium term

Confidence

High

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

OVERWEIGHT

Catalysts

  • ACN is in a severe technical downtrend — the price sits ~43% below the 200-day SMA, and both the 50- and 200-day SMAs are declining, with no signs of flattening.
  • The MACD is deeply negative (−14.02) but may be very modestly narrowing; this is the only glimmer of potential momentum exhaustion, but it is too early to call a bottom.
  • RSI has recovered from oversold extremes (from ~20 to ~33) — this suggests some buying interest has entered, but a reading of 33 is still consistent with bearish conditions.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

ACN Research Note

Full desk note for Jul 1, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

23 min read

WebserviceX · Agentic Research Desk

ACN Equity Research Note

Published Jul 1, 2026 · Desk view OVERWEIGHT · Generated 2026-07-02T20:22:50Z · Maintained by Walter Vijayakumar · Methodology · Track record

ACN Stock Rating Summary

ACN bias

OVERWEIGHT

Horizon

Short to medium term

ACN key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

ACN catalyst watch

ACN is in a severe technical downtrend — the price sits ~43% below the 200-day SMA, and both the 50- and 200-day SMAs are declining, with no signs of flattening.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

High

How the call aged · 5D

—Awaiting market dataPeer 55p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-07-02T20:45:10.701338+00:00.

5D move

—

2026-07-01 → awaiting

Outcome

Awaiting market data

5D trend

+1.53%

Vol (20D ann.)

+72.10%

vs SPY: -0.17%

Close 131.13 → — (USD, vendor closes)

Batch scorecard · 2026-07-01 · ACN

Publish QC

passed
Expand

Pipeline fingerprint 2f45a102687f75c0

Trace 639536e1…

No QC issues recorded.